tetano
Editor, Senior Moderator
Antimicrob Agents Chemother
. 2020 Jul 6;AAC.01101-20.
doi: 10.1128/AAC.01101-20. Online ahead of print.
Clinical Trials of Repurposed Antivirals for SARS-CoV-2
Miguel Angel Martinez[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir/ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized controlled trials are showing the poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals.
. 2020 Jul 6;AAC.01101-20.
doi: 10.1128/AAC.01101-20. Online ahead of print.
Clinical Trials of Repurposed Antivirals for SARS-CoV-2
Miguel Angel Martinez[SUP] 1 [/SUP]
Affiliations
- PMID: 32631826
- DOI: 10.1128/AAC.01101-20
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir/ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized controlled trials are showing the poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals.